TransMedics Group, Inc. (TMDX) is a publicly traded company in the Healthcare sector, operating within the Medical - Devices industry. The company is headquartered in Andover, MA, United States. The current CEO is Waleed H. Hassanein.
TMDX has IPO date of 2019-05-02, 728 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $3.97B.
TransMedics Group, Inc. is a commercial-stage medical technology company headquartered in Andover, Massachusetts, focused on transforming organ transplant therapy for end-stage organ failure patients globally. The company develops and commercializes the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring platform that uses proprietary technology to maintain near-physiologic conditions for donor organs outside the human body. Its product portfolio includes OCS LUNG for lung preservation, OCS Heart for cardiac preservation, and OCS Liver for hepatic preservation, each designed to improve transplant outcomes and expand the pool of viable organs. Founded in 1998, TransMedics addresses critical challenges in organ transplantation through innovative ex vivo organ preservation technology.
